The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma

The development of several treatment options over the last 2 decades has led to a notable improvement in the survival of patients with multiple myeloma. Despite these advances, the disease remains incurable for most patients. Moreover, standard combinations of alkylating agents, immunomodulatory dru...

Descripción completa

Detalles Bibliográficos
Autores: Oriol, Albert|||0000-0001-6804-2221, Abril, Laura, Torrent, Anna, Ibarra, Gladys, Ribera, Jose-Maria|||0000-0003-1042-6024
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:270650
Acceso en línea:https://ddd.uab.cat/record/270650
https://dx.doi.org/urn:doi:10.1177/20406207211019622
Access Level:acceso abierto
id ES_39cd7ac5f00c8b4a50a67786563f77f6
oai_identifier_str oai:ddd.uab.cat:270650
network_acronym_str ES
network_name_str España
repository_id_str
spelling The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myelomaOriol, Albert|||0000-0001-6804-2221Abril, LauraTorrent, AnnaIbarra, GladysRibera, Jose-Maria|||0000-0003-1042-6024The development of several treatment options over the last 2 decades has led to a notable improvement in the survival of patients with multiple myeloma. Despite these advances, the disease remains incurable for most patients. Moreover, standard combinations of alkylating agents, immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies targeting CD38 and corticoids are exhausted relatively fast in a proportion of high-risk patients. Such high-risk patients account for over 20% of cases and currently represent a major unmet medical need. The challenge of drug resistance requires the development of highly active new agents with a radically different mechanism of action. Several immunotherapeutic modalities, including antibody-drug conjugates and T-cell engagers, appear to be promising choices for patients who develop resistance to standard combinations. Chimeric antigen-receptor-modified T cells (CAR-Ts) targeting B-cell maturation antigen have demonstrated encouraging efficacy and an acceptable safety profile compared with alternative options. Multiple CAR-Ts are in early stages of clinical development, but the first phase III trials with CAR-Ts are ongoing for two of them. After the recent publication of the results of a phase II trial confirming a notable efficacy and acceptable safety profile, idecabtagene vicleucel is the first CAR-T to gain regulatory US Food and Drug Administration approval to treat refractory multiple myeloma patients who have already been exposed to antibodies against CD38, proteasome inhibitors, and immunomodulatory agents and who are refractory to the last therapy. Here, we will discuss the preclinical and clinical development of idecabtagene vicleucel and its future role in the changing treatment landscape of relapsed and refractory multiple myeloma.Universitat Autònoma de Barcelona 22021-01-0120212021-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/270650https://dx.doi.org/urn:doi:10.1177/20406207211019622reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2706502026-06-06T12:50:31Z
dc.title.none.fl_str_mv The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
title The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
spellingShingle The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
Oriol, Albert|||0000-0001-6804-2221
title_short The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
title_full The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
title_fullStr The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
title_full_unstemmed The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
title_sort The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
dc.creator.none.fl_str_mv Oriol, Albert|||0000-0001-6804-2221
Abril, Laura
Torrent, Anna
Ibarra, Gladys
Ribera, Jose-Maria|||0000-0003-1042-6024
author Oriol, Albert|||0000-0001-6804-2221
author_facet Oriol, Albert|||0000-0001-6804-2221
Abril, Laura
Torrent, Anna
Ibarra, Gladys
Ribera, Jose-Maria|||0000-0003-1042-6024
author_role author
author2 Abril, Laura
Torrent, Anna
Ibarra, Gladys
Ribera, Jose-Maria|||0000-0003-1042-6024
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
description The development of several treatment options over the last 2 decades has led to a notable improvement in the survival of patients with multiple myeloma. Despite these advances, the disease remains incurable for most patients. Moreover, standard combinations of alkylating agents, immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies targeting CD38 and corticoids are exhausted relatively fast in a proportion of high-risk patients. Such high-risk patients account for over 20% of cases and currently represent a major unmet medical need. The challenge of drug resistance requires the development of highly active new agents with a radically different mechanism of action. Several immunotherapeutic modalities, including antibody-drug conjugates and T-cell engagers, appear to be promising choices for patients who develop resistance to standard combinations. Chimeric antigen-receptor-modified T cells (CAR-Ts) targeting B-cell maturation antigen have demonstrated encouraging efficacy and an acceptable safety profile compared with alternative options. Multiple CAR-Ts are in early stages of clinical development, but the first phase III trials with CAR-Ts are ongoing for two of them. After the recent publication of the results of a phase II trial confirming a notable efficacy and acceptable safety profile, idecabtagene vicleucel is the first CAR-T to gain regulatory US Food and Drug Administration approval to treat refractory multiple myeloma patients who have already been exposed to antibodies against CD38, proteasome inhibitors, and immunomodulatory agents and who are refractory to the last therapy. Here, we will discuss the preclinical and clinical development of idecabtagene vicleucel and its future role in the changing treatment landscape of relapsed and refractory multiple myeloma.
publishDate 2021
dc.date.none.fl_str_mv 2
2021-01-01
2021
2021-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/270650
https://dx.doi.org/urn:doi:10.1177/20406207211019622
url https://ddd.uab.cat/record/270650
https://dx.doi.org/urn:doi:10.1177/20406207211019622
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406194064424961
score 15.301603

Similares en LA Referencia